These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 37716012)
1. Self-Adaptive Nanoregulator to Mitigate Dynamic Immune Evasion of Pancreatic Cancer. Pan J; Lai Y; Zhang S; Zhang H; Shan Y; Huang L; Wang F; Yu H; Xu L; Xu Z Adv Mater; 2023 Nov; 35(47):e2305798. PubMed ID: 37716012 [TBL] [Abstract][Full Text] [Related]
2. Extracellular vesicle-packaged lncRNA from cancer-associated fibroblasts promotes immune evasion by downregulating HLA-A in pancreatic cancer. Yao H; Huang C; Zou J; Liang W; Zhao Y; Yang K; Zhong Z; Zhou S; Li J; Li Y; Xu L; Huang K; Lian G J Extracell Vesicles; 2024 Jul; 13(7):e12484. PubMed ID: 39041344 [TBL] [Abstract][Full Text] [Related]
3. Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1-Dependent Immune Evasion. Yang Y; Stang A; Schweickert PG; Lanman NA; Paul EN; Monia BP; Revenko AS; Palumbo JS; Mullins ES; Elzey BD; Janssen EM; Konieczny SF; Flick MJ Cancer Res; 2019 Jul; 79(13):3417-3430. PubMed ID: 31048498 [TBL] [Abstract][Full Text] [Related]
4. CDK1/2/5 inhibition overcomes IFNG-mediated adaptive immune resistance in pancreatic cancer. Huang J; Chen P; Liu K; Liu J; Zhou B; Wu R; Peng Q; Liu ZX; Li C; Kroemer G; Lotze M; Zeh H; Kang R; Tang D Gut; 2021 May; 70(5):890-899. PubMed ID: 32816920 [TBL] [Abstract][Full Text] [Related]
5. Opportunities and delusions regarding drug delivery targeting pancreatic cancer-associated fibroblasts. Liu H; Shi Y; Qian F Adv Drug Deliv Rev; 2021 May; 172():37-51. PubMed ID: 33705881 [TBL] [Abstract][Full Text] [Related]
6. Targeting the tumor microenvironment for pancreatic ductal adenocarcinoma therapy. Zhang YF; Jiang SH; Hu LP; Huang PQ; Wang X; Li J; Zhang XL; Nie HZ; Zhang ZG Chin Clin Oncol; 2019 Apr; 8(2):18. PubMed ID: 31070038 [TBL] [Abstract][Full Text] [Related]
7. Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options. Kabacaoglu D; Ciecielski KJ; Ruess DA; Algül H Front Immunol; 2018; 9():1878. PubMed ID: 30158932 [TBL] [Abstract][Full Text] [Related]
8. Patched 1-interacting Peptide Represses Fibrosis in Pancreatic Cancer to Augment the Effectiveness of Immunotherapy. Oyama Y; Onishi H; Koga S; Murahashi M; Ichimiya S; Nakayama K; Fujimura A; Kawamoto M; Imaizumi A; Umebayashi M; Ohuchida K; Morisaki T; Nakamura M J Immunother; 2020 May; 43(4):121-133. PubMed ID: 31834207 [TBL] [Abstract][Full Text] [Related]
9. Immune evasion on the nanoscale: Small extracellular vesicles in pancreatic ductal adenocarcinoma immunity. Fyfe J; Dye D; Razak NBA; Metharom P; Falasca M Semin Cancer Biol; 2023 Nov; 96():36-47. PubMed ID: 37748738 [TBL] [Abstract][Full Text] [Related]
10. Transforming Cancer-Associated Fibroblast Barrier into Drug Depots to Boost Chemo-Immunotherapy in "Shooting Fish in a Barrel" Pattern. Yuan S; Mu W; Liu S; Liu M; Xia Z; Liang S; Gao T; Fu S; Liu J; Huang X; Liu Y; Zhang N ACS Nano; 2023 Jul; 17(14):13611-13626. PubMed ID: 37326384 [TBL] [Abstract][Full Text] [Related]
11. Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment. Garcia Garcia CJ; Huang Y; Fuentes NR; Turner MC; Monberg ME; Lin D; Nguyen ND; Fujimoto TN; Zhao J; Lee JJ; Bernard V; Yu M; Delahoussaye AM; Jimenez Sacarello I; Caggiano EG; Phan JL; Deorukhkar A; Molkentine JM; Saur D; Maitra A; Taniguchi CM Gastroenterology; 2022 Jun; 162(7):2018-2031. PubMed ID: 35216965 [TBL] [Abstract][Full Text] [Related]
12. A Photoactivatable Self-Assembled Nanoagonist for Synergistic Therapy against Pancreatic Ductal Adenocarcinoma. Xu X; Li T; Yang T; Liu F; Guo Z; Wu H; Tang Y; Chen H Nano Lett; 2024 Oct; 24(39):12239-12248. PubMed ID: 39248330 [TBL] [Abstract][Full Text] [Related]
13. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer. Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616 [TBL] [Abstract][Full Text] [Related]
14. Inter- and intra-tumoural heterogeneity in cancer-associated fibroblasts of human pancreatic ductal adenocarcinoma. Neuzillet C; Tijeras-Raballand A; Ragulan C; Cros J; Patil Y; Martinet M; Erkan M; Kleeff J; Wilson J; Apte M; Tosolini M; Wilson AS; Delvecchio FR; Bousquet C; Paradis V; Hammel P; Sadanandam A; Kocher HM J Pathol; 2019 May; 248(1):51-65. PubMed ID: 30575030 [TBL] [Abstract][Full Text] [Related]
15. The Tango between Cancer-Associated Fibroblasts (CAFs) and Immune Cells in Affecting Immunotherapy Efficacy in Pancreatic Cancer. Stouten I; van Montfoort N; Hawinkels LJAC Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37240052 [TBL] [Abstract][Full Text] [Related]
17. A nanodrug simultaneously inhibits pancreatic stellate cell activation and regulatory T cell infiltration to promote the immunotherapy of pancreatic cancer. Wang R; Hong K; Zhang Q; Cao J; Huang T; Xiao Z; Wang Y; Shuai X Acta Biomater; 2023 Oct; 169():451-463. PubMed ID: 37572982 [TBL] [Abstract][Full Text] [Related]
18. IL1-Induced JAK/STAT Signaling Is Antagonized by TGFβ to Shape CAF Heterogeneity in Pancreatic Ductal Adenocarcinoma. Biffi G; Oni TE; Spielman B; Hao Y; Elyada E; Park Y; Preall J; Tuveson DA Cancer Discov; 2019 Feb; 9(2):282-301. PubMed ID: 30366930 [TBL] [Abstract][Full Text] [Related]
19. Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma. Fan JQ; Wang MF; Chen HL; Shang D; Das JK; Song J Mol Cancer; 2020 Feb; 19(1):32. PubMed ID: 32061257 [TBL] [Abstract][Full Text] [Related]
20. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer. Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]